AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05607498
Drug: EMB07
RxNorm normalized name: Emtricitabine/Bictegravir/Tenofovir Alafenamide
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: EMB07 is a MAT-Fab bispecific antibody against CD3 and RORI
Trial: NCT04706013
Drug: Pyridoxal Phosphate
RxNorm normalized name: Pyridoxal phosphate
DrugBank: Pyridoxal phosphate (DB00114)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets 50 mg
Trial: NCT03493165
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: mTOR inhibitor
Trial: NCT05629143
Drug: Alginate
RxNorm normalized name: Alginate
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients will stop their intake of PPIs and use alginate. After one month, patients will stop their intake of alginates.
Trial: NCT04585477
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants in the intervention arm will receive Durvalumab (1500 mg IV every 4 weeks for up to 12 months) as monotherapy or 20mg/kg if weight is 30kg or less.
Trial: NCT04585477
Drug: Durvalumab (Imfinzi) alone or in combination with platinum-based chemotherapy
RxNorm normalized name: durvalumab Injection [Imfinzi]
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants in the intervention arm (Cohort 1 MRD+) will receive a fixed dose of Durvalumab (1500 mg IV every 4 weeks for up to 12 months), either as monotherapy or in combination with a platinum-based chemotherapy regimen (investigator's choice). Platinum-based chemotherapy options include carboplatin, cisplatin, pemetrexed, paclitaxel, or nab-paclitaxel, administered per standard of care for up to 4 cycles.
Trial: NCT06649825
Drug: Vitamin B1
RxNorm normalized name: Vitamin B1
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B1 tablets, 100mg bid, taken orally for one year
Trial: NCT05542407
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg/kg- 20 mg/kg Atezolizumab will be administered by intravenous, on day 1 of each 21-day cycle.
Trial: NCT05758415
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The participants will receive Secukinumab 300 mg s.c. at randomization (Baseline visit), Week 1, 2, 3, 4, 8, and 12
Trial: NCT05451407
Drug: Toripalimab injection
RxNorm normalized name: toripalimab Injection
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibody against Programmed death factor receptor 1
Trial: NCT05480488
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subjects will receive a single oral dose of 2 mg midazolam (Treatment A, B, and C).
Trial: NCT05480488
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive a single oral dose of 25 mg warfarin (Treatment A and B).
Trial: NCT05480488
Drug: Daridorexant
RxNorm normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive an o.d. oral dose of 50 mg daridorexant from Day 1 to Day 7 of Treatment B and a single oral dose of 50 mg daridorexant on Day 1 of Treatment C.
Trial: NCT05093790
Drug: Ticagrelor
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05093790
Drug: BMS-986141
RxNorm normalized name: BMS-986141
DrugBank: BMS-986141 (DB14942)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05093790
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06417476
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Trial: NCT06417476
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 85 mg/m² iv drip over 2 hours on day 1, repeated every 14 days.
Trial: NCT05734625
Drug: Bupivacaine HCl 0.5% Injectable Solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will receive 0.5 ml (supratrochlear) to 1.0 ml (supraorbital, auriculotemporal) to 1.25 ml (greater and lesser occipital) for each nerve block.
Trial: NCT05734625
Drug: Methylprednisolone 40 MG Injection
RxNorm normalized name: methylprednisolone 40 MG Injection
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Will receive 10 mg (0.25 ml) mixed with 1.25 ml Bupivacaine 0.5% for each greater and lesser occipital nerve block if MPNB group or 20 mg (0.5 ml) methylprednisolone in each GON if GONB group.
Trial: NCT06246422
Drug: Tranexamic Acid 500 MG
RxNorm normalized name: tranexamic acid 500 MG
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local instillation of 500 mg tranexamic acid in 20 ml normal saline in the gall bladder bed
Trial: NCT05784012
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab 500 mg IV every 21 days in neoadjuvant and adjuvant stage.
Trial: NCT05784012
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib 200 or 300mg orally administered QD in neoadjuvant, concurrent with radiotherapy and adjuvant stage until completing week 48.
Trial: NCT05784012
Drug: cisplatin plus radiotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the concurrent phase
Trial: NCT05784012
Drug: Niraparib
RxNorm normalized name: Niraparib
DrugBank: Niraparib (DB11793)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Niraparib 200 or 300mg orally administered QD (Neoadjuvant and Maintenance stages).
Trial: NCT04297254
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib capsules.
Trial: NCT06607692
Drug: Olaparib; 177Lu-DOTATATE
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 7Lu-DOTATATE will be administered intravenously, on day 1, every 8 weeks, at a fixed dose of 200 mCi (7.4 GBq) for children \&gt;= 12 years old infused intravenously over a period of 30 minutes. For children younger than 12 years old, the dose that will be administered is 200 MBq per kilogram of body weight (maximum 7.4 GBq) infused intravenously over a period of 30 minutes. Concomitant to 177Lu-DOTATATE, patients will receive IV fluids and an IV infusion of amino acid solution for renal protection23. Patients will receive four infusions every 8 weeks (maximum cumulative radioactivity, 29.6 GBq \[800 mCi\]). Olaparib will be administered PO, BID, days 2-29, every 8 weeks at a fixed dose of 187.5mg/m2 twice daily (BID).
Trial: NCT04643379
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Supplied by Merck \& Co.
Trial: NCT04643379
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Supplied by Merck \& Co.
Trial: NCT04643379
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercially available
Trial: NCT05826509
Drug: Peri-operative darolutamide + surgery.
DrugBank: Darolutamide (DB12941)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Darolutamide: 600 mg (2 tablets of 300 mg) twice daily with food, equivalent to a total daily dose of 1200 mg; for a total duration of 9 months. Darolutamide will start at day 1.~Surgery: radical prostatectomy with lymph node dissection will be performed after at least 3 months of darolutamide treatment.
Trial: NCT04638309
Drug: APR-548 + Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: APR-548 monotherapy period followed by APR-548 in combination with Azacitidine
Trial: NCT06424301
Drug: Targeting NUDT21 siRNA drugs
RxNorm normalized name: Sirna-027
DrugBank: Sirna-027 (DB05896)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is performed for intravitreal chemotherapy.
Trial: NCT06299371
Drug: Adebrelimab
RxNorm normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adebrelimab IV
Trial: NCT06299371
Drug: paclitaxel for injection (albumin bound)
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel for injection (albumin bound) IV
Trial: NCT06299371
Drug: Cisplatin or Carboplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin or Carboplatin IV
Trial: NCT05631678
Drug: ASK120067;itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
Trial: NCT05063149
Drug: Broncho-Vaxom
RxNorm normalized name: Broncho-Vaxom
DrugBank: OM85 (DB16533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broncho-Vaxom is a bacterial extract comprising lyophilised fractions of 21 different inactivated bacterial strains, which are frequently causing RTI.
Trial: NCT06652685
Drug: D5-PBCR(-) IA arm
RxNorm normalized name: MAGNESIUM ALUMINOMETASILICATE TYPE IA
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction: IA Drug: idarubicin, intravenously, 10 mg/m\^2 on D1-3 Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group with favorable/intermediate risk and MRD negetive, will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses. Subjects in the group with adverse risk or MRD positive will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status.
Trial: NCT06652685
Drug: D5-PBCR(+) IA+Venetoclax arm
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Induction: IA+Ven Drug: idarubicin, intravenously, 10 mg/m\^2, on D1-3, Drug: cytarabine, intravenously, 100 mg/m\^2 on D1-7 For D5-PBCR (+) patients, Venetoclax will be combined. Drug: Venetoclax. Orally once daily, on D6-14. A 3-day dose ramp-up is required for the first induction (100mg D6, 200mg D7, 400mg D8-14) If a second induction is needed, the dose of IA is the same as the first cycle, and dose ramp-up of venetoclax is not required.~Consolidation:~Subjects who achieve composite complete remission (CRc) proceed with consolidation therapy.~In consolidation therapy phase, subjects in the group will receive cytarabine intravenously at 2g/m\^2/q12h\*6 doses together with venetoclax 400mg on D4-10. Dose ramp-up of venetoclax is not required.~After two cycles of consolidation, a multi-disciplinary team will discuss whether the patient need allogeneic hematopoietic stem-cell transplant (allo-HSCT) according to ELN risk stratification and MRD status.
Trial: NCT04576507
Drug: Cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigates two strengths of cannabis.
Trial: NCT04221750
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally starting at 500 mg (one tablet) taken orally once a day with meals. After a week, the dose of metformin will be increased to 1000 mg (two tablets) daily. After another week, the dose of metformin will be increased to 1500 mg (three tablets) daily.
Trial: NCT06005324
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given as part of induction chemotherapy.
Trial: NCT06005324
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given as part of induction chemotherapy.
Trial: NCT06005324
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given as part of induction chemotherapy.
Trial: NCT06701344
Drug: Golidocitinib
RxNorm normalized name: Golidocitinib
DrugBank: Golidocitinib (DB18057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance Treatment:~Complete remission patients will further divide into two groups. Unfit, frail old patients will receieve Golidocitinib 150mg QD for two years. Fit, young patients will receive ASCT.
Trial: NCT06700681
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIVA induction and maintain with Propofol.
Trial: NCT06700681
Drug: Remimazolam
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TIVA induction and maintain with Remimazolam.
Trial: NCT06005324
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given as part of CRT regimen (7 weekly doses). Investigator will choose the appropriate chemotherapy backbone to be given during CRT.
Trial: NCT05212857
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given subcutaneously or as an injection
Trial: NCT05212857
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given subcutaneously or as an injection
Trial: NCT05212857
Drug: Triptorelin acetate
RxNorm normalized name: triptorelin acetate
DrugBank: Triptorelin (DB06825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given subcutaneously or as an injection
Trial: NCT05212857
Drug: Degarelix acetate
RxNorm normalized name: Degarelix acetate
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given subcutaneously or as an injection
Trial: NCT05212857
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given orally
Trial: NCT05212857
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given orally
Trial: NCT05212857
Drug: Enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT06702826
Drug: Cadonilimab combined with SRS
RxNorm normalized name: miconazole
DrugBank: Cadonilimab (DB16680)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible subjects were treated with stereotactic radiotherapy for brain metastases plus Cadonilimab followed by maintenance therapy with Cadonilimab alone
Trial: NCT04717830
Drug: Gamezumab
RxNorm normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solution for infusion
Trial: NCT00000803
Drug: Delavirdine mesylate
RxNorm normalized name: Delavirdine Mesylate
DrugBank: Delavirdine (DB00705)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000803
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000803
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05196711
Drug: MAX-40070
RxNorm normalized name: Bronkaid Max
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the SAD phase, the proposed doses will be increased gradually. Each cohort will consist of 8 subjects, with 6 subjects randomly assigned to MAX-40070.~During the MAD phase, the treatment will be administered once a day for 14 consecutive days.
Trial: NCT06702566
Drug: chemotherapy drugs
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy drugs are determined based on the investigator's decision.
Trial: NCT06703437
Drug: Dehydrated alcohol
RxNorm normalized name: DEHYDRATED ALCOHOL
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-acting neuraxial blockade at the time of prostate biopsy by periprostatic injection of Dehydrated alcohol.
Trial: NCT06703437
Drug: Lidocaine IV
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: By periprostatic injection, 2mL
Trial: NCT06703047
Drug: ATRA+pd-1+chemo
RxNorm normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All trans tretinoic acid+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
Trial: NCT06703047
Drug: placebo+PD-1+chemo
RxNorm normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo+tislelizumab+chemotherapy (paclitaxel, cisplatin, or carboplatin)
Trial: NCT04942964
Drug: Bocidelpar
RxNorm normalized name: Bocidelpar
DrugBank: Bocidelpar (DB16906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04950608
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, single administration, dosage 25 mg orally
Trial: NCT05268627
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: endoscopy
Trial: NCT04444362
Drug: Intestinal Microbiota Transplant (IMT) Capsules
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intestinal Microbiota Transplant (IMT) Capsules tid immediately after cardiovascular surgery for at least 7 days
Trial: NCT04848337
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
Trial: NCT04848337
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 20 mg orally daily.
Trial: NCT06087419
Drug: chidamide
RxNorm normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 30mg twice weekly (BIW) for induction phase (cycle1-2,28 days per cycle)
Trial: NCT06087419
Drug: Venetoclax Oral Tablet
RxNorm normalized name: venetoclax Oral Tablet
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400mg daily d1-14 induction phase (cycle1-2, 28 days per cycle)
Trial: NCT06087419
Drug: Inotuzumab Ozogamicin
RxNorm normalized name: Inotuzumab ozogamicin
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.6 mg/m2 on day 1 of cycle 1-2(28 days per cycle)
Trial: NCT05442216
Drug: Tagraxofusp (Cycles 1-2)
RxNorm normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12 mcg/kg intravenously Days 1-5
Trial: NCT05442216
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75 mg/m2 intravenously Days 1-7 (Cycle 3-12)
Trial: NCT05442216
Drug: Tagraxofusp (Cycles 3-12)
RxNorm normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 12 mcg/kg intravenously Days 1-3
Trial: NCT06477783
Drug: Teclistamab
RxNorm normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention is part of standard clinical care, as Tecvayli/Teclistamab is reimbursed for this group of patients.
Trial: NCT05595447
Drug: Brentuximab Vedotin 50 MG [Adcetris]
RxNorm normalized name: brentuximab vedotin 50 MG [Adcetris]
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab plus blocked PD-1 plus ASCT plus maintenance Brentuximab plus blocked PD-1
Trial: NCT05963997
Drug: Samuraciclib
RxNorm normalized name: Samuraciclib
DrugBank: Samuraciclib (DB16061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samuraciclib capsules by mouth once a day
Trial: NCT05963997
Drug: Elacestrant Dihydrochloride
RxNorm normalized name: elacestrant dihydrochloride
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elacestrant tablets by mouth once a day
Trial: NCT05341583
Drug: Ensartinib
RxNorm normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensartinib 225 mg once daily until disease recurrence or up to 2 years, whichever occurs earlier.
Trial: NCT05565105
Drug: Thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thiotepa: 5 mg/kg/day IV over approximately 4 hours daily x 2 (Day -5 and Day -4).
Trial: NCT05565105
Drug: Busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan: 0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics